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doi:10.1016/j.jfma.2011.08.003Background/Purpose: Despite general recommendation of short-course antibiotic prophylaxis,
prolonged antibiotic use is still commonly reported in clinical settings. This study compared
the efficacy of 1-day versus 3-day antibiotic prophylaxis in preventing surgical site infection
(SSI) in patients undergoing coronary artery bypass graft (CABG).
Methods: This prospective, randomized control study was performed in a tertiary-care medical
center from June 2002 to April 2004. Patients underwent non-emergency CABG and were
randomized into two groups receiving either 1 day or 3 days cefazolin prophylaxis. The SSI
rates were compared between the two groups.
Results: During the study period, 231 patients were enrolled, 120 in the 1-day group and 111 in
the 3-day group. Twenty-two episodes of SSI were observed within 1 month after operation: 13
(10.8%) in the 1-day group and nine (8.1%) in the 3-day group (odds ratio: 1.37; 95% confidence
interval: 0.56e3.33; pZ 0.48). By logistic regression analysis, 1-day prophylaxis with cefazolin
was not associated with higher risk of SSI (adjusted odds ratio: 0.91; 95% confidence interval:
0.32e2.56; p Z 0.85).Chang, Department of Internal Medicine, National Taiwan University Hospital, #7 Chung-Shan South
tw (S.-C. Chang).
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620 M.-H. Lin et al.Conclusion: Antibiotic prophylaxis for 1 day in CABG surgery was associated with similar rates
of postoperative infection compared with antibiotic prophylaxis of 3 days.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Prophylactic antibiotics can prevent surgical site infection
(SSI) in cardiac surgery. This was clearly demonstrated in
the 1980s by two large double-blind placebo-controlled
studies.1,2 The antibiotics administrated before induction
can effectively reduce SSI from 50% to approximately 20%.3
Cephalosporin is widely used as the prophylactic antibiotic
in cardiac surgery, because it is effective against most
Staphylococcus aureus and coagulase-negative staphylo-
cocci, the primary pathogens infecting these patients per-
ioperatively.4 However, as to the optimal duration of
prophylactic antibiotics, there is still a wide difference in
clinical settings, which ranges from 1 dose to 5 days.5e8
The aim of prophylactic antibiotic use is to prevent
contamination while operating9; therefore, timely and
adequate administration is more important than prolonged
use of antibiotics. Furthermore, prolonged use of prophy-
lactic antibiotics not only provokes the worry of increased
drug side effects and increased risk for developing infections
due to drug-resistant pathogens, but also increases medical
costs. In a prospective observational study, Harbarth et al
have reported that prolonged use of prophylactic antibiotics
[beyond 48 hours after coronary artery bypass graft (CABG)]
is significantly associated with increased antimicrobial
resistance from clinical specimens, such as resistant Enter-
obacteriaceae and Enterococcus.10
As to prophylactic antibiotics for cardiac surgery, Nooyen
et al have reported in a prospective randomized study that
a single dose of cefuroxime was as effective as a 3-day
course for prevention of wound infection.11 However, the
power of that study was low due to the limited number of
cases. The overall infection rate (including sternal and leg
wound) was also lower (5.3%) when compared with other
studies. This might have been due to routine nasal admin-
istration of topical disinfectant to eliminate S. aureus.
To elucidate the effect of the duration of prophylactic
antibiotics, we conducted a prospective, randomized
control study to compare the effectiveness of preventing
SSI after CABG using 1-day or 3-day antibiotic prophylaxis.Patients and methodsStudy design
This prospective, randomized, parallel-group controlled
study enrolled patients who underwent CABG surgery from
June 2002 to April 2004 in National Taiwan University
Hospital, a tertiary-care medical center in Northern Taiwan.
Patients who met the inclusion criteria were randomized
to receive cefazolin for 1 day or 3 days. Surgical wounds,
laboratory data, relevant medical examination, and medi-
cations were assessed and recorded daily by infection
control personnel during hospitalization. Post-discharge
follow-up continued until 1 month after operation. The
diagnosis of SSI was made by an attending physicianaccording to the definition of the United States Centers for
Disease Control and Prevention (US CDC).4
Study population
Patients who underwent non-emergency CABG surgery and
were18 years oldwere eligible for this study. Patients were
excluded if they fulfilled one of the following exclusion
criteria: existing preoperative infections; undergoing treat-
ment with antibiotics; hypersensitivity to cefazolin; renal
dysfunction (serum creatinine level >2 mg/dL or creatinine
clearance < 35 mL/min, or under hemodialysis treatment);
left ventricular ejection fraction <30%; obesity (body mass
index >31 kg/m2); chronic obstructive pulmonary disease
(COPD); undergoing combined surgery other than CABG;
neutropenia (leukocyte count <1000/cm3); pregnancy or
undertaking breastfeeding; or refusal of consent.
Study procedure
Patients were assessed for eligibility preoperatively. Nasal
swab screening for methicillin-sensitive S. aureus (MSSA) or
methicillin-resistant S. aureus (MRSA) carriage was per-
formed 1 day before surgery. Mupirocin or other decoloni-
zation agents were not used for MRSA colonizers in our
institution. Patients were randomized to receive 1 day or
3 days cefazolin prophylaxis for CABG, by a computer-
generated code. Patients received 1 g cefazolin within 1
hour prior to incision, and an additional dose was allowed if
it was a prolonged operation (1 more dose for every 3e4
operation hours).4 The 1-day prophylaxis group received 1 g
cefazolin every 8 hours for three doses after the operation,
and the 3-day group received 1 g cefazolin every 8 hours for
nine doses after the operation. For each patient, the
surgical wound was assessed by the attending physician.
Data regarding potential risk factors for SSI were
collected, including preoperative risk factors [sex, height,
weight, age, body mass index, pulmonary disease, renal
disease, diabetes mellitus, smoking, hypertension, hyper-
cholesterolemia, preoperative hospitalization days, length
of preoperative stay in the intensive care unit (ICU),
urgency of the procedure (urgency was defined as medical
factors requiring the patient to stay in the hospital to have
the operation before discharge)]; perioperative risk factors
[surgeon, American Society of Anesthesiologists (ASA)
score, duration of surgery, numbers of CABGs, number of
internal mammary arteries used for grafting, use of extra-
corporeal bypass, intra-aortic balloon pumping (IABP),
extracorporeal membrane oxygenation, external pace-
maker, dialysis, and units of transfused blood]; and post-
operative risk factors (time of catheters remaining in
patients, length of stay in the ICU, and relevant medical
examination and medications). Preoperative, postoperative
day 1 and postoperative day 6 blood levels sugar were also
recorded.
Antibiotic prophylaxis for coronary artery bypass graft 621Clinical outcome
The primary endpoint was SSI occurring up to 1 month after
surgery. The definition of SSI was based on the criteria of the
US CDC.4 SSI was diagnosed by the attending physician and
any controversial cases were evaluated by another inde-
pendent infectious disease specialist, who was unaware of
the assignment of the patients. For each SSI, details with
regards to site of infection and causative pathogen were
collected. Details of other infections and complications after
surgery were also collected.
Statistical analysis
Analyses were performed according to intent-to-treat and
per protocol analyses. In the per protocol analysis, patients
with prolonged prophylactic antibiotic usage for longer than
the study assigned, defined as prolonged antibiotic usage
without documented evidence of infection, were excluded.
The categorical variables were compared by c2 test or
Fisher’s exact test, and continuous variables were compared
by Student’s t test. Stepwise multivariate logistic regression
analyses were undertaken to identify the risk factors for SSI.
Variables with p < 0.1 in univariate analysis were included
in the multivariate model. A p value <0.05 was considered
significant. Statistical analysis was performed by Stata
version 9.0 (StataCorp, College Station, TX, USA).Table 1 Preoperative characteristics and risk factors of patien
Variable Intent-to-treat analy
1eday group
(n Z 120)
3eday g
(n Z 11
Male 94 (78.3%) 90 (81.1
Age (yr) 64.4  9.6 65.5 
Body mass index (kg/m2) 25.0  2.8 25.1 
Underlying diseases
Hypertension 80 (66.7%) 75 (67.6
Diabetes mellitus 52 (43.3%) 43 (38.7
Smoking 46 (38.3%) 34 (30.6
COPD 3 (2.5%) 0 (0%)
Hyperlipidemia 59 (49.2%) 60 (54.1
Renal impairment 4 (3.3%) 2 (1.8%)
Previous cardiac surgery 0 (0%) 2 (1.8%)
Urgency of the procedure
Elective 94 (78.3%) 81 (73.0
Urgent 26 (21.7%) 30 (27.0
Preoperative intensive care 9 (7.5%) 13 (11.7
LVEF 58.1  13.6 59.5 
Nasal swab screeninga
Positive for Staphylococcus aureus 14 (12.7%) 20 (19.4
MSSA carrier 8 (7.3%) 16 (15.5
MRSA carrier 6 (5.5%) 4 (3.9%)
Continuous variables are expressed as mean  standard deviation.
COPDZ chronic obstructive pulmonary disease; LVEFZ left ventricul
aureus; MRSA Z methicillin-resistant S. aureus.
a Nasal swab screening was performed in 110 and 103 participants in
analysis; and in 72 and 64 participants in the 1-day group and 3-day gResults
Baseline characteristics
From June 2002 to April 2004, 331 patients were assessed for
eligibility and 97 were excluded, including five due to
obesity, 10 to existing preoperative infection, one to chronic
obstructive pulmonary disease, 28 to renal disease, eight to
left ventricular ejection fraction <30%, 13 to combined
surgery other than CABG, 16 to emergency CABG, and 16 who
were unwilling to participate in the study. Thus, a total of
234 patients were included and informed consent was
obtained from all of them. Three patients died immediately
after surgery and were excluded from further analysis. Nasal
swabs for MRSA carriage screening were obtained in 213
patients. Ten of these were identified as MRSA nasal carriers.
Intent-to-treat analysis
There were 120 patients in the 1-day group and 121 in the
3-day group. The baseline characteristics, such as sex,
height, weight, age, body mass index, underlying diseases,
smoking status, preoperative hospitalization days, and
length of preoperative stay in the ICU were similar in the
two groups (Table 1). As to the variables associated with
perioperative risk factors, such as surgeon, ASA score,
duration of surgery, numbers of CABGs, number of internalts
sis (n Z 231) Per protocol analysis (n Z 150)
roup
1)
P value 1eday group
(n Z 80)
3eday group
(n Z 70)
P value
%) 0.60 67 (83.8%) 57 (81.4%) 0.71
11.5 0.45 65.1  10.0 65.0  11.6 0.92
2.9 0.84 24.8  2.8 25.0  2.7 0.64
%) 0.88 56 (70.0%) 44 (62.9%) 0.36
%) 0.48 32 (40.0%) 23 (32.9%) 0.37
%) 0.22 33 (41.3%) 18 (25.7%) 0.05
0.25 3 (3.8%) 0 (0%) 0.25
%) 0.46 40 (50.0%) 41 (58.6%) 0.29
0.69 3 (3.8%) 0 (0%) 0.25
0.23 0 (0%) 2 (2.86%) 0.22
%) 0.34 63 (75.8%) 52 (74.3%) 0.52
%) 17 (21.3%) 18 (25.7%)
%) 0.28 7 (8.8%) 6 (8.6%) 0.97
12.0 0.51 57.8  13.0 60.9  13.5 0.25
%) 0.18 8 (11.1%) 13 (20.3%) 0.14
%) 0.06 4 (5.6%) 11 (17.2%) 0.05
0.75 4 (5.6%) 2 (3.1%) 0.68
ar ejection fraction; MSSAZ methicillin-sensitive Staphylococcus
the 1-day group and 3-day group, respectively, in intent-to-treat
roup, respectively, in per protocol analysis.
Table 2 Perioperative characteristics and risk factors of patients
Variable Intent-to-treat analysis (n Z 231) Per protocol analysis (n Z 150)
1eday group
(n Z 120)
3eday group
(n Z 111)
p 1eday group
(n Z 80)
3eday group
(n Z 70)
p
ASA score 3.2  0.4 3.3  0.5 0.44 3.2  0.4 3.2  0.5 0.94
Surgeon
A 22 (18.3%) 21 (18.9%) 0.91 11 (13.8%) 11 (15.7%) 0.73
B 31 (25.8%) 33 (29.7%) 0.51 20 (25.0%) 19 (27.1%) 0.77
C 42 (35.0%) 41 (36.4%) 0.76 32 (40.0%) 28 (40.0%) 1.00
Others 25 (20.8%) 16 (14.4%) 0.20 17 (21.3%) 12 (17.1%) 0.53
Mean duration of operation (hr) 4.4  1.1 4.5  1.2 0.62 4.4  1.1 4.4  1.1 0.72
Mean time of 1st ABP administration
before incision (min)
17.6  20.4 17.9  13.3 0.90 15.3  22.9 18.4  10.8 0.30
Mean dose of ABP added during operation 1.1  0.3 1.1  0.5 0.13 1.1  0.4 1.1  0.5 0.41
Extracorporeal bypass 3 (2.5%) 6 (5.4%) 0.32 1 (1.3%) 4 (5.7%) 0.19
Mean number of IMAs 1.1  0.3 1.1  0.3 0.18 1.1  0.3 1.1  0.4 0.48
Mean number of CABGs 3.2  0.8 3.1  0.9 0.38 3.3  0.9 3.0  0.7 0.10
IABP 4 (0.33) 5 (4.5) 0.74 0 (0%) 2 (2.9) 0.22
ECMO 0 (0%) 1 (0.9%) 0.48 0 (0%) 0 (0%)
External pacemaker 0 (0%) 1 (0.9%) 0.48 0 (0%) 0 (0%)
Reopen 0 (0%) 3 (2.7%) 0.11 0 (0%) 0 (0%)
Dialysis 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Blood transfusion (U) 4.2  4.9 5.3  5.7 0.14 3.8  4.7 4.9  5.8 0.21
Continuous variables are expressed as mean  standard deviation.
American Society of Anesthesiologists; ABP Z antibiotic prophylaxis; IMA Z internal mammary artery; CABGZ coronary artery bypass
graft; IABP Z intra-aortic balloon pumping; ECMO Z extracorporeal membrane oxygenation.
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bypass, IABP, extracorporeal membrane oxygenation,
external pacemaker, receiving dialysis, and number of units
of transfused blood, there were no significant differences
between the two groups (Table 2).
Postoperative factors, such as the time that the cathe-
ters remained in the patients, were similar, except that the
time for the central venous catheters (CVCs) was higher in
the 3-day group (4.3 days vs. 3.7 days in the 1-day group,
p Z 0.03) (Table 3).
Biochemistry and hemography were similar in both
groups, except that the postoperative hemoglobin level was
significantly higher in the 3-day group (12.4 g/dL vs. 11.9 g/
dL in the 1-day group, p Z 0.03) (Table 4).
In total, there were 22 episodes of SSI after CABG,
including 13 in the 1-day group (10.8%) and nine in theTable 3 Postoperative characteristics and risk factors of patien
Variable Intent-to-treat analysis (n Z
1eday group
(n Z 120)
3eday group
(n Z 111)
Ventilator (hr) 13.9  7.4 17.3  30.1
CVP (d) 3.7  1.4 4.3  2.6
Arterial catheter (d) 3.4  3.2 3.4  1.5
Chest tube (d) 4.1  1.4 4.2  1.6
Foley catheter (d) 4.3  1.1 4.5  1.7
Peripheral catheter (d) 4.3  2.7 5.0  4.4
Continuous variables are expressed as mean  standard deviation.
d Z days; hr Z hours.3-day group (8.1%). For the rate of SSI, there was no
significant difference between the 1-day and 3-day groups
(p Z 0.48). The mean time to infection was 15.3  5.1
days. The mean time between operation and development
of SSI in the 1-day group was significantly shorter than the
3-day group (12.8  3.3 days and 18.9  5.3 days, respec-
tively, p Z 0.004) (Table 5). By combining the SSI rate and
timing of SSI, we performed an “SSI-free” analysis to
compare the 1-day and 3-day groups, and there was no
significant difference [p Z 0.44, 95% confidence interval
(CI): 0.31e1.68] (Fig. 1).
Gram-positive bacteria were the main causative patho-
gens for SSI, including six episodes caused by MSSA, six by
coagulase-negative staphylococci, and five by MRSA. There
was no significant difference as to the causative pathogens
between the 1-day and 3-day groups (Table 5).ts
231) Per protocol analysis (n Z 150)
p 1eday group
(n Z 80)
3eday group
(n Z 70)
p
0.24 12.4  6.1 13.5  8.5 0.39
0.03 3.5  1.0 4.2  2.1 0.008
0.99 3.4  3.8 3.3  0.9 0.75
0.45 4.0  1.3 4.1  1.3 0.83
0.30 4.1  0.8 4.3  1.0 0.20
0.13 3.9  2.3 4.0  3.5 0.81
Table 4 Hemography and biochemistry characteristics and risk factors of patients
Variable Intent-to-treat analysis (n Z 231) Per protocol analysis (n Z 150)
1eday group
(n Z 120)
3eday group
(n Z 111)
p 1eday group
(n Z 80)
3eday group
(n Z 70)
p
Preoperative
Glucose (mg/dL) 127.3  46.9 128.8  54.2 0.83 123.4  47.6 121.8  42.6 0.84
WBCs (/mL) 6583  1669 6468  1978 0.63 6307  1337 6223  1755 0.74
Segment (%) 62.5  9.5 60.4  9.0 0.11 61.9  8.7 59.4  9.2 0.13
Lymphocytes (%) 27.2  9.0 28.6  8.8 0.28 27.6  8.8 29.8  8.7 0.17
Hemoglobin(g/dL) 13.1  1.5 13.3  1.6 0.47 13.1  1.6 13.5  1.5 0.15
Creatinine (mg/dL) 1.1  0.3 1.1  0.3 0.95 1.1  0.3 1.1  0.3 0.75
Albumin (g/dL) 4.3  0.4 4.2  0.1 0.08 1.3  0.3 4.2  0.4 0.41
Postoperative day 6
Glucose (mg/dL) 148.2  53.3 145.2  49.4 0.70 148.2  52.5 135.9  38.4 0.17
WBCs (/mL) 7913  2253 7684  2664 0.48 7555  2019 6987  1726 0.07
Segment (%) 65.8  8.8 65.3  8.2 0.65 65.3  8.8 64.0  8.2 0.37
Lymphocytes (%) 20.4  6.9 21.8  6.7 0.13 21.1  7.1 23  6.7 0.10
Hemoglobin (g/dL) 11.9  1.8 12.4  1.8 0.03 11.8  1.7 12.4  1.7 0.04
Creatinine (mg/dL) 1.1  0.3 1.1  0.3 0.63 1.1  0.3 1.1  0.2 0.24
Albumin (g/dL) 3.6  0.4 3.6  0.4 0.77 3.7  0.4 3.6  0.4 0.74
C-reactive protein 4.6  3.1 4.7  4.3 0.72 4.3  2.7 3.8  2.8 0.41
Continuous variables are expressed as mean  standard deviation.
WBCs Z white blood cells.
Antibiotic prophylaxis for coronary artery bypass graft 623The total number of hospitalization days was 15.1  5.2
days in the 1-day group and 16.7  9.1 days in the 3-day
group, and there was no significant difference between the
groups (pZ 0.1). There was also no difference with regard
to postoperative hospitalization days, and a trend for
longer postoperative stay in the ICU in the 3-day group
(Table 5). After excluding death immediately after CABGTable 5 Postoperative outcome
Outcome Intent-to-treat analysis
1eday group
(n Z 120)
3eday gro
(n Z 111)
30 day SSI 13 (10.8%) 9 (8.1%)
Sternal wound infection 6 (5.0%) 3 (2.7%)
Deep 3 (2.5%) 1 (0.9%)
Superficial 3 (2.5%) 2 (1.8%)
Harvest site infection 7 (5.8%) 6 (5.4%)
All cause mortality 0 0
Postoperative intensive care
stay (d)
2.2  0.9 2.6  1.6
Postoperative hospital stay (d) 12.1  3.6 13.3  8.3
Total hospital stay (d) 15.1  5.2 16.7  9.1
Time to SSI (d) 12.8  3.3 18.9  5.3
Pathogens
MSSA 3 (2.5%) 3 (2.7%)
MRSA 2 (1.7%) 3 (2.7%)
CNS 4 (3.3%) 2 (1.8%)
Klebsiella pneumoniae 1 (0.8%) 0 (0%)
Polymicrobial 2 (1.7%) 0 (0%)
Not available 1 (0.8%) 1 (0.9%)
SSI Z surgical site infection; MSSA Z methicillin-sensitive Stap
CNS Z coagulase-negative staphylococci.(within 1 day), there was no mortality within 1 month after
CABG in both groups.
Multivariate analysis was used to identify the risk factors
for SSI after CABG. The potential risk factors, identified as
p < 0.1 by univariate analysis (data not shown), were
included in the multivariate analysis. Duration of prophy-
lactic antibiotics (1-day group vs. 3-day group) was forced(n Z 231) Per protocol analysis (n Z 150)
up p 1eday group
(n Z 80)
3eday group
(n Z 70)
p
0.48 12 (15.0%) 5 (7.1%) 0.13
0.50 5 (6.3%) 2 (2.9%) 0.45
0.62 3 (3.8%) 0 (0%) 0.25
1.00 2 (2.5%) 2 (2.9%) 1.00
0.89 7 (8.8%) 3 (4.3%) 0.34
0 0
0.05 2.1  0.6 2.5  1.0 0.003
0.17 12.3  3.9 12.4  4.6 0.86
0.10 15  0 4.9 15.7  6.5 0.43
0.004 12.5  3.2 18  5.7 0.02
1.00 3 (3.8%) 2 (2.9%) 1.00
0.67 2 (2.5%) 1 (1.4%) 1.00
0.69 4 (5.0%) 2 (2.9%) 0.69
1.00 1 (1.3%) 0 (0%) 1.00
0.50 2 (2.5%) 0 (0%) 0.50
1.00 0 0
hylococcus aureus; MRSA Z methicillin-resistant S. aureus;
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Figure 1 Surgical site infection (SSI)-free curve for the
patients in the 1-day group and 3-day group. The SSI-free
probability for the patients in the 1-day group was not signifi-
cantly different from that in the 3-day group (p Z 0.44).
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Figure 2 Surgical site infection (SSI)-free curve for patients
in the 1-day group and 3-day group, excluding those who
received prolonged antibiotic treatment. The SSI-free proba-
bility for the patients in the 1-day group was not significantly
different from that in the 3-day group (p Z 0.18).
624 M.-H. Lin et al.into the multivariate analysis. We found that 1-day
prophylaxis with cefazolin was not associated with higher
risk of SSI [adjusted odds ratio (OR): 0.91; 95% CI:
0.32e2.56; p Z 0.85). Nasal MRSA carriage was correlated
with higher risk of SSI (adjusted OR: 9.8; 95% CI:
1.88e51.41; pZ 0.007). High postoperative serum albumin
level (adjusted OR: 0.1; 95% CI: 0.04e0.64; p Z 0.01) and
hyperlipidemia (adjusted OR: 0.3; 95% CI: 0.10e0.97;
p Z 0.04) were correlated with lower risk of SSI (Table 6).
Per protocol analysis
There were 40 patients in the 1-day group (33.3%) and 41 in
the 3-day group (36.9%) who violated the protocol for
duration of prophylactic antibiotics and received more than
three doses and nine doses of cefazolin, respectively,
without any diagnosis of infection. After excluding these
patients, there were 150 patients, with 80 and 70 patients
in the 1-day group and 3-day group, respectively.
The baseline characteristics were not significantly
different between the patients receiving 1-day or 3-day
antibiotic prophylaxis, except for longer CVC duration and
higher postoperative hemoglobin level in the 3-day group,
which was also observed in the intent-to-treat analysis
(Tables 1e4).Table 6 Multivariate analysis of risk factors for surgical site inf
Variate Intent-to-treat analysis (n Z
AOR 95% CI
1-day group 0.91 0.32e2.56
Postoperative albumin
level (g/dL)
0.1 0.04e0.64
MRSA carrier 9.8 1.88e51.41
Hyperlipidemia 0.3 0.10e0.97
Urgency d d
CVC (d) d d
AOR Z adjusted odds ratio; CI Z confidence interval; MRSA Z me
catheter.For the per protocol patients, there was also no signifi-
cant difference in SSI rate after CABG between the 1-day
and 3-day groups (OR: 2.27; 95% CI: 0.77e6.67; p Z 0.14).
The mean duration between operation and development of
SSI in the 1-day group was also significantly shorter than in
the 3-day group (12.5  3.2 days vs. 18.0  5.7 days,
p Z 0.02). There were no significant differences in the
overall hospital stay and postoperative hospital stay, but
postoperative ICU stay was significant longer in the 3-day
group (p Z 0.003) (Table 5). By combining the SSI rate
and timing of SSI, we performed an “SSI-free” analysis to
compare the 1-day group and 3-day group, and there was no
significant difference (95% CI: 0.17e1.40; p Z 0.18)
(Fig. 2).
There was also no difference as to the causative path-
ogens for SSI, mortality, total days of hospitalization or
duration of postoperative hospitalization, except that the
postoperative ICU stay was longer in the 3-day group
(2.5  1.0 days vs. 2.1  0.6 days in the 1-day group,
p Z 0.003) (Table 5).
By multivariate analysis, the 1-day group was not asso-
ciated with higher risk of SSI (adjusted OR: 1.67; 95% CI:
0.4e7.69; p Z 0.46). MRSA carriage and urgent CABG were
associated with higher risk of SSI, whereas CVC usage andection after coronary artery bypass graft
231) Per protocol analysis (n Z 150)
p AOR 95% CI p
0.85 1.67 0.4e7.69 0.46
0.01 0.03 0.002e0.40 0.008
0.007 57.9 4.73e709.15 0.001
0.04 d d d
d 8.95 1.90e42.18 0.006
d 0.4 0.180.98 0.04
thicillin-resistant Staphylococcus aureus; CVC Z central venous
Antibiotic prophylaxis for coronary artery bypass graft 625high postoperative albumin level were associated with
lower risk of SSI after CABG (Table 6).Discussion
In this prospective, randomized controlled study, we
demonstrated that patients who received 1 day prophy-
lactic cefazolin did not have a significantly higher rate of
postoperative SSI after CABG, as compared with patients
who received 3 days prophylaxis. Under the overall SSI rate
of 9.5%, which was comparable with the SSI rate after CABG
of 1e10% in the literature,12 there was no significant
difference regarding the rate of SSI between the 1-day
group and 3-day group. This is believed to be the first
study to compare the effectiveness of preventing SSI after
CABG surgery using a different duration of cefazolin, which
is the recommended prophylactic antibiotic in Taiwan and
many other parts of the world.13,14 Our results are
comparable with those of other studies using different
prophylactic antibiotics. Nooyen et al have reported that
a single dose of cefuroxime is as effective as a 3-day course
in the prevention of wound infection in CABG.11 Kriaras
et al have compared the effects of preventing SSI by
a single dose of cefuroxime or amoxicillin plus netilmicin
for 4 days, and have also shown no significant difference.15
The SSI rate in the donor leg site as 5.6% was slightly
higher than that observed in the National Nosocomial
Infection Surveillance, which was around 0.6e1.48%.16 This
might have been due to our prospective and daily active
surveillance in the present study, in which more cases
would have been detected than in other studies with
passive surveillance in normal clinical settings.
By multivariate logistic regression analysis, we found
that the risk factor for developing SSI after CABG was MRSA
nasal carriage in both the intent-to-treat and per protocol
analyses, rather than duration of antibiotic prophylaxis.
Nasal carriage of S. aureus has previously been identified as
a risk factor for SSI after major cardiac surgery.17,18 Munoz
et al have reported that, among 357 patients undergoing
major cardiac surgery, nasal carriage of S. aureus was a risk
factor for postoperative SSI (relative risk Z 2.51%;
p Z 0.01), and was especially higher for MRSA carriage
(relative risk Z 5.27; p Z 0.002).19 In our study, we also
found that MRSA carriage had a higher risk for SSI (SSI
rate Z 0.3; OR: 5.37; 95%CI: 1.26e22.93; p Z 0.02) but
MSSA carriage did not carry a higher risk (SSI rate Z 0.04;
OR: 0.44; 95% CI: 0.06e3.46; p Z 0.44). Even though nasal
carriage rate of S. aureus or MRSA in our study (16.0% and
4.7%, respectively) was lower than that reported by Munoz
et al (27% and 9.4%), we still found that MRSA carriage was
an independent risk factor for developing SSI after CABG.
As to the other secondary outcomes, there was no
difference in overall duration of hospitalization, site of SSI,
or causative pathogen for SSI among the two groups. There
was no mortality observed within 1 month of operation,
except for three deaths immediately after surgery. Inter-
estingly, we noted that the timing for SSI onset was later for
the group receiving 3 days antibiotic prophylaxis. However,
there was no significant difference in the incidence of SSI
and duration of hospitalization, even though prolonged use
of antibiotics might be associated with delayed onset of SSI.One limitation of this study was that 35% of patients
received a longer duration of cefazolin treatment than the
study assigned. Although the study design had been clearly
explained and discussed with the cardiac surgeons before
conducting the study, the surgeons were still free to adjust
the antibiotic treatment according to the condition of the
patients. We found no significant difference in most of the
baseline clinical characteristics between those fulfilling
the assigned duration of antibiotic prophylaxis and those
violating the study protocol in terms of antibiotic duration.
The exception was that the preoperative white blood cell
count would be higher among those violating the study
protocol in the 1-day group (p Z 0.009), and that the
patients who received IABP would tend to receive pro-
longed antibiotic prophylaxis in the 1-day group (pZ 0.01),
which might have led to some selection bias. However, the
number of the patients who received IABP was small
(4 patients only in the 1-day group), therefore, selection bias
might have been limited. Furthermore, there was no signif-
icant difference as to the major outcome, the SSI rate, in
those fulfilling the assigned duration of antibiotic prophy-
laxis and those violating the study protocol in terms of
antibiotic duration. Among the other secondary outcomes,
we noted that those violating the study protocol in the 1-day
group tended to have longer ICU stays (pZ 0.003). However,
this could have been multifactorial, because there was no
significant correlation between duration of ICU stay and
prolonged antibiotic use after adjusting for other con-
founding factors such as sex; age; duration of IABP, CVC,
Foley catheter or ventilator use; and preoperative and
postoperative white blood cell count (p Z 0.11) (data not
shown). However, to prevent possible selection bias, we
further conducted the per protocol analysis, for which we
excluded patients who received longer scheduled antibiotic
prophylaxis (nZ 81). There was still no difference as to SSI
rate between the 1-day group and 3-day group.
One important limitation of this study was that the
assignment of treatment course was not blinded. However,
the definition of SSI is well described and 91% of SSIs were
proven by positive culture. The extent of possible bias due
to unblinded design would have been limited. In addition, if
the patient had equivocal manifestations of infection,
a diagnosis of SSI would have been made by an independent
infectious disease specialist who did not know the assign-
ment of the prophylaxis duration.
Another limitation of our study was that the sample size
was not large enough to achieve the estimated power. The
average SSI rate after CABG in our institution was 4e6%
(Chang, unpublished data); therefore, we would have
needed 343 patients in each group to achieve 80% power.
However, in the baseline characteristics analysis, we did
not notice a significant difference among the other possible
risk factors for SSI, except longer postoperative ICU stay in
the 3-day group (both in the intent-to-treat and per-
protocol analyses). Thus, we used multivariate logistic
regression analysis to adjust this possible confounding
factor and demonstrate that the duration of antibiotic
prophylaxis was not a risk factor for SSI after CABG.
Our study excluded those patients with a higher risk for
post-CABG infection, such as obesity, chronic renal disease,
and heart failure. Therefore, our results can only apply to
lower-risk patients undergoing CABG surgery. Besides, most
626 M.-H. Lin et al.of the patients received CABG procedures with the off-pump
technique (without extracorporeal bypass), and thus our
result should be applied carefully to other CABG procedures.
In summary, even though SSI rate was slightly higher
among patients in the 1-day group, there was no significant
difference with the 3-day group. We suggest that 1 day
prophylactic use of cefazolin is adequate and effective for
SSI prevention after CABG. Further study is needed to
address this issue in high-risk patients. In addition, because
MRSA carriage is an independent risk factor for SSI after
CABG, the need for routine screening and mupirocin
decolonization treatment to help decrease the risk of
infection needs to be studied further.
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